2025
Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study
Prunas O, Tiu A, Shioda K, Bansal S, Weinberger D. Evaluating the association between routine pneumococcal vaccination and COVID-19 severity among older adults in the United States: A case control study. Vaccine X 2025, 24: 100622. DOI: 10.1016/j.jvacx.2025.100622.Peer-Reviewed Original ResearchCOVID-19 patientsCase-control studyIntensive care unitSevere respiratory symptomsPneumococcal vaccineSevere outcomesRespiratory symptomsOdds of progressionReceipt of pneumococcal vaccinationCOVID-19 severitySevere COVID-19 outcomesLogistic regression modelsSevere acute respiratory syndrome coronavirus 2Streptococcus pneumoniaeAcute respiratory syndrome coronavirus 2Non-severeRespiratory syndrome coronavirus 2Care unitControlled studiesPatientsSyndrome coronavirus 2COVID-19 outcomesSARS-CoV-2VaccineCoronavirus 2In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients
Mack P, Crawford J, Chang A, Yin A, Klein S, Shea P, Hirsch F, Zidar D, Simon V, Gleason C, McBride R, Cordon-Cardo C, VanOudenhove J, Halene S, Lee F, Mantis N, Kushi L, Weiskopf D, Merchant A, Reckamp K, Skarbinski J, Figueiredo J. In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients. Journal Of The National Cancer Institute 2025, djaf073. PMID: 40127178, DOI: 10.1093/jnci/djaf073.Peer-Reviewed Original ResearchChanging public health landscapePublic health landscapeEnrollment of participantsSARS-CoV-2National Cancer InstituteRisk of SARS-CoV-2 infectionU.S. National Cancer InstituteNational Institute of AllergyOverall healthHealth landscapeSelf-reportCohort studyStudy designBiospecimen collectionInstitute of AllergySARS-CoV-2 infectionCancer InstituteStandard serological testsData elementsStudy immune responsesHematologic malignanciesClinicopathological dataNational InstituteCancer patientsCOVID-19Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus
Bajema K, Bui D, Yan L, Li Y, Rajeevan N, Vergun R, Berry K, Huang Y, Lin H, Aslan M, Ioannou G. Severity and Long-Term Mortality of COVID-19, Influenza, and Respiratory Syncytial Virus. JAMA Internal Medicine 2025, 185: 324-334. PMID: 39869355, PMCID: PMC11773409, DOI: 10.1001/jamainternmed.2024.7452.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusLong-term mortalitySARS-CoV-2Syncytial virusCohort studyAssociated with higher long-term mortalityRisk differenceIntensive care unit admissionSeasonal influenza vaccineRetrospective cohort studyDisease severity of COVID-19Long-term deathAssociated with more severe disease outcomesRisk of deathCompare disease severitySevere disease outcomesRisk of hospitalizationSeverity of COVID-19Same-day testingInfluenza vaccineInverse probability weightingUnit admissionCumulative incidenceMortality of COVID-19Primary outcomeImpact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis
Sumsuzzman D, Ye Y, Wang Z, Pandey A, Langley J, Galvani A, Moghadas S. Impact of disease severity, age, sex, comorbidity, and vaccination on secondary attack rates of SARS-CoV-2: a global systematic review and meta-analysis. BMC Infectious Diseases 2025, 25: 215. PMID: 39948450, PMCID: PMC11827239, DOI: 10.1186/s12879-025-10610-5.Peer-Reviewed Original ResearchConceptsPopulation settingEffective public health strategiesConfidence intervalsImpact of disease severityModified Newcastle-Ottawa ScalePublic health strategiesHigher secondary attack rateRisk of biasNewcastle-Ottawa ScalePandemic responseGlobal systematic reviewRandom-effects modelFreeman-Tukey double arcsine transformationWeb of ScienceNo significant associationDrivers of SARS-CoV-2 transmissionHealth strategiesSecondary attack rateSARS-CoV-2Disease severityEffective pandemic responseTargeted interventionsDouble arcsine transformationOvid MEDLINESystematic reviewTargeting the SARS-CoV-2 reservoir in long COVID
Proal A, Aleman S, Bomsel M, Brodin P, Buggert M, Cherry S, Chertow D, Davies H, Dupont C, Deeks S, Ely E, Fasano A, Freire M, Geng L, Griffin D, Henrich T, Hewitt S, Iwasaki A, Krumholz H, Locci M, Marconi V, Mehandru S, Muller-Trutwin M, Painter M, Pretorius E, Price D, Putrino D, Qian Y, Roan N, Salmon D, Tan G, VanElzakker M, Wherry E, Van Weyenbergh J, Yonker L, Peluso M. Targeting the SARS-CoV-2 reservoir in long COVID. The Lancet Infectious Diseases 2025, 25: e294-e306. PMID: 39947217, DOI: 10.1016/s1473-3099(24)00769-2.Peer-Reviewed Original ResearchSARS-CoV-2Duration of treatmentPotential combination approachSARS-CoV-2 persistenceSARS-CoV-2 infectionPost hoc analysisHIV reservoirHepatitis CMechanism of actionPatient subgroupsInterpretation of trialsDebilitating disease statesPrecision oncologyMonoclonal antibodiesGrowing body of evidenceBody of evidenceEffect of Bacille Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2 and COVID‐19 vaccination
Messina N, Germano S, Chung A, van de Sandt C, Stevens N, Allen L, Bonnici R, Croda J, Counoupas C, Grubor‐Bauk B, Haycroft E, Kedzierska K, McDonald E, McElroy R, Netea M, Novakovic B, Perrett K, Pittet L, Purcell R, Subbarao K, Triccas J, Lynn D, Curtis N, Davidson A, Gardiner K, Gwee A, Jamieson T, Messina N, Morawakage T, Perlen S, Perrett K, Pittet L, Sastry A, Teo J, Orsini F, Lee K, Moore C, Vidmar S, Pittet L, Ali R, Dunn R, Edler P, Gell G, Goodall C, Hall R, Krastev A, La N, McDonald E, McPhate N, Nguyen T, Ren J, Stevens L, Messina N, Alamrousi A, Bonnici R, Dang T, Hua J, Razmovska M, Reddiex S, Wang X, Anderson J, Azzopardi K, Bennett‐Wood V, Czajko A, Mazarakis N, McCafferty C, Oppedisano F, Ortika B, Pell C, Spry L, Toh R, Velagapudi S, Vlahos A, Wee‐Hee A, Ramos P, De La Cruz K, Gamage D, Karunanayake A, Mezzetti I, Ong B, Singh R, Sooriyarachchi E, Nicholson S, Cain N, Brizuela R, Huang H, Abruzzo V, Bealing M, Bimboese P, Bowes K, Burrell E, Chan J, Cushnahan J, Elborough H, Elkington O, Fahey K, Fernandez M, Flynn C, Fowler S, Andrit M, Gladanac B, Hammond C, Ma N, Macalister S, Milojevic E, Mojeed J, Nguyen J, O'Donnell L, Olivier N, Ooi I, Reynolds S, Shen L, Sherry B, Spotswood J, Wedderburn J, Younes A, Legge D, Bell J, Cheah J, Cobbledick A, Lim K, Elia S, Addlem L, Bourke A, Brophy C, Henare N, Jenkins N, Machingaifa F, Miller S, Mitchell K, Pitkin S, Wall K, Villanueva P, Crawford N, Pittet L, Norton W, Tan N, Chengodu T, Dawson D, Gordon V, Korman T, O'Bryan J, Abruzzo V, Agius S, Bannister S, Bucholc J, Burns A, Camesella B, Carlin J, Ciaverella M, Curtis M, Firth S, Guo C, Hannan M, Hill E, Joshi S, Lieschke K, Mathers M, Odoi S, Rak A, Richards C, Steve L, Stewart C, Sudbury E, Thomson H, Watts E, Williams F, Young A, Glenn P, Kaynes A, De Floy A, Buchanan S, Sondag T, Xie I, Edmund H, Byrne B, Keeble T, Ngien B, Noonan F, Wearing‐Smith M, Clarke A, Davies P, Eastwood O, Ellinghaus A, Ghieh R, Hilton Z, Jennings E, Kakkos A, Liang I, Nicol K, O'Callaghan S, Osman H, Rajaram G, Ratcliffe S, Rayner V, Salmon A, Scheppokat A, Stevens A, Street R, Toogood N, Wood N, Bahaduri T, Baulman T, Byrne J, Carter C, Corbett M, Dao A, Desylva M, Dunn A, Gardiner E, Joyce R, Kandasamy R, Munns C, Pelayo L, Sharma K, Sterling K, Uren C, Colaco C, Douglas M, Hamilton K, Bartlett A, McMullan B, Palasanthiran P, Williams P, Beardsley J, Bergant N, Lagunday R, Overton K, Post J, Al‐Hindawi Y, Barney S, Byrne A, Mead L, Plit M, Lynn D, Benson S, Blake S, Botten R, Chern T, Eden G, Griffith L, James J, Lynn M, Markow A, Sacca D, Stevens N, Wesselingh S, Doran C, Barry S, Sawka A, Evans S, Goodchild L, Heath C, Krieg M, Marshall H, McMillan M, Walker M, Richmond P, Amenyogbe N, Anthony C, Arnold A, Arrowsmith B, Ben‐Othman R, Clark S, Dunnill J, Eiffler N, Ewe K, Finucane C, Flynn L, Gibson C, Hartnell L, Hollams E, Hutton H, Jarvis L, Jones J, Jones J, Jones K, Kent J, Kollmann T, Lalich D, Lee W, Lim R, McAlister S, McDonald F, Meehan A, Minhaj A, Montgomery L, O'Donnell M, Ong J, Ong J, Parkin K, Perez G, Power C, Rezazadeh S, Richmond H, Rogers S, Schultz N, Shave M, Skut P, Stiglmayer L, Truelove A, Wadia U, Wallace R, Waring J, England M, Latkovic E, Manning L, Herrmann S, Lucas M, Lacerda M, Andrade P, Barbosa F, Barros D, Brasil L, Capella A, Castro R, Costa E, de Souza D, Dias M, Dias J, Ferreira K, Figueiredo P, Freitas T, Furtado A, Gama L, Godinho V, Gouy C, Hinojosa D, Jardim B, Jardim T, Junior J, Lima A, Maia B, Marins A, Mazurega K, Medeiros T, Melo R, Moraes M, Nascimento E, Neves J, Oliveira M, Oliveira T, Oliveira I, Otsuka A, Paes R, Pereira H, Pereira G, Prado C, Queiroz E, Rodrigues L, Rodrigues B, Sampaio V, Santos A, Santos D, Santos T, Santos E, Sartim A, Silva A, Silva J, Silva E, Simão M, Soares C, Sousa A, Trindade A, Val F, Vasconcelos A, Vasconcelos H, Croda J, Abreu C, Almeida K, de Andrade C, Angelo J, de Araújo Arcanjo G, Arruda B, Ayala W, Barbosa A, Batista F, de Morais Batista F, de Jesus Costa M, Croda M, da Cruz L, Diogo R, Escobar R, Fernandes I, Figueiredo L, Gonçalves L, Lahdo S, dos Santos Lencina J, de Lima G, Matos L, Meireles B, Moreira D, Muranaka L, de Oliveira A, de Oliveira K, de Oliveira M, de Oliveira R, dos Reis Pereira A, Puga M, Ramos C, da Rosa T, dos Santos K, dos Santos C, dos Santos D, Santos K, da Silva P, da Silva P, dos Santos Silva D, da Silva P, da Rosa Soares B, Sperotto M, Tadokoro M, Tsuha D, Vieira H, Dalcolmo M, da Paixão C, Castro G, Collopy S, da Costa Silva R, da Silveira S, Da‐Cruz A, de Carvalho A, de Cássia Batista R, De Freitas M, de Oliveira Ferreira A, de Souza A, Doblas P, dos Santos A, dos Santos V, Dos Santos G, dos Santos Gomes D, Fortunato A, Gomes‐Silva A, Gonçalves M, Meireles P, da Costa Carvalho E, do Couto Motta F, de Mendonça L, dos Santos Pandine G, Pereira R, Maia I, da Rocha J, Romano J, da Silva E, de Siqueira M, Soares Á, Bonten M, Arroyo S, Aymerich C, Besten H, Boon A, Brakke K, Janssen A, Koopmans M, Lemmens T, Leurink T, Septer‐Bijleveld E, Stadhouders K, Troeman D, van der Waal M, van Opdorp M, van Sluis N, Wolters B, Kluytmans J, Romme J, van den Bijllaardt W, van Mook L, van Rijen M, Filius P, Gisolf J, Greven F, Huijbens D, Hassing R, Pon R, Preijers L, van Leusen J, Verheij H, Boersma W, Brans E, Kloeg P, Molenaar‐Groot K, Nguyen N, Paternotte N, Rol A, Stooper L, Dijkstra H, Eggenhuizen E, Huijs L, Moorlag S, Netea M, Pranger E, Taks E, Oever J, Heine R, Blauwendraat K, Meek B, Erkaya I, Harbech H, Roescher N, Peeters R, Riele M, Zhou C, Calbo E, Marti C, Palomares E, Porcuna T, Barriocanal A, Barriocanal A, Casas I, Dominguez J, Esteve M, Lacoma A, Latorre I, Molina G, Molina B, Rosell A, Vidal S, Barrera L, Bustos N, Calderón I, Campos D, Carretero J, Castellano A, Compagnone R, de Arellano E, de la Serna A, del Toro Lopez M, Espindola M, Gutierrez A, Hernandez A, Jiménez V, Moreno E, Navarrete N, Paño T, Rodríguez‐Baño J, Tristán E, Villegas M, Garces A, Amo E, Guerrero R, Goikoetxea J, Jorge L, Perez C, Álvarez M, Cuadra M, de las Revillas Almajano F, Garcia P, Poderos T, Rico C, Sanchez B, Valero O, Vega N, Campbell J, Barnes A, Catterick H, Cranston T, Dawe P, Fletcher E, Fouracre L, Gifford A, Gow N, Kirkwood J, Martin C, McAndrew A, Mitchell M, Newman G, O'Connell A, Onysk J, Quinn L, Rhodes S, Stone S, Symons L, Tripp H, Warris A, Watkins D, Whale B, Harding A, Lockhart G, Sidaway‐Lee K, Campbell J, Hilton S, Manton S, Webber‐Rookes D, Winder R, Moore J, Bateman F, Gibbons M, Knight B, Moss J, Statton S, Studham J, Hall L, Moyle W, Vent T. Effect of Bacille Calmette–Guérin vaccination on immune responses to SARS‐CoV‐2 and COVID‐19 vaccination. Clinical & Translational Immunology 2025, 14: e70023. PMID: 39872402, PMCID: PMC11761716, DOI: 10.1002/cti2.70023.Peer-Reviewed Original ResearchBacille Calmette-Guerin vaccineBacille Calmette-GuerinImmune response to vaccinationMultiplex bead arrayResponse to SARS-CoV-2Response to vaccinationT cellsSARS-CoV-2Control groupCytokine responsesBead arraySARS-CoV-2-specific T cell responsesCOVID-19 vaccineIntracellular cytokine staining assayT cell cytokine productionImmune response to SARS-CoV-2Antigen-specific antibody responsesActivation-induced markersT cell responsesWhole-blood cytokine responsesT cell activationSARS-CoV-2-specific antibodiesDose of ChAdOx1BNT162b2 vaccineCytokine productionIncidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study
Vernon S, Zheng T, Do H, Marconi V, Jason L, Singer N, Natelson B, Sherif Z, Bonilla H, Taylor E, Mullington J, Ashktorab H, Laiyemo A, Brim H, Patterson T, Akintonwa T, Sekar A, Peluso M, Maniar N, Bateman L, Horwitz L, Hess R. Incidence and Prevalence of Post-COVID-19 Myalgic Encephalomyelitis: A Report from the Observational RECOVER-Adult Study. Journal Of General Internal Medicine 2025, 1-10. PMID: 39804551, DOI: 10.1007/s11606-024-09290-9.Peer-Reviewed Original ResearchSARS-CoV-2 infectionLongitudinal observational cohort studyClinical diagnostic criteriaSelf-reported symptomsResultsThe incidence rateBackgroundMyalgic encephalomyelitis/chronic fatigue syndromeTiming of SARS-CoV-2 infectionPost-exertional malaiseObservational cohort studyUninfected participantsPost-acuteSARS-CoV-2Diagnostic criteriaCohort studyHazard ratioStudy visitsFatigue syndromeParticipantsEnhanced recoveryME/CFS symptomsLong COVIDMyalgic encephalomyelitisDays of infectionPrevalenceInfected participantsHousehold transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants
Baker J, Nakayama J, O’Hegarty M, McGowan A, Teran R, Bart S, Sosa L, Brockmeyer J, English K, Mosack K, Bhattacharyya S, Khubbar M, Yerkes N, Campos B, Paegle A, McGee J, Herrera R, Pearlowitz M, Williams T, Kirking H, Tate J. Household transmission of SARS-CoV-2 in five US jurisdictions: Comparison of Delta and Omicron variants. PLOS ONE 2025, 20: e0313680. PMID: 39787187, PMCID: PMC11717262, DOI: 10.1371/journal.pone.0313680.Peer-Reviewed Original ResearchConceptsPublic health jurisdictionsTransmission riskGeneralized estimating equationsHealth jurisdictionsSARS-CoV-2 transmissionSARS-CoV-2Household contactsIndex casePrevention strategiesRisk estimatesImpact SARS-CoV-2 transmissionConfidence intervalsSymptom statusMultivariate modelUS jurisdictionsSARS-CoV-2 DeltaEstimate differencesHousehold transmission rateOmicron variantSocial factorsSource of SARS-CoV-2 transmissionCOVID-19 vaccine dosesSARS-CoV-2 variantsRiskSymptomatic index casesAutopsy: Infectious and Serious Communicable Diseases
Gill J, Brooks E. Autopsy: Infectious and Serious Communicable Diseases. 2025, 455-467. DOI: 10.1016/b978-0-443-21441-7.00021-2.Peer-Reviewed Original ResearchHuman immunodeficiency virusViral hepatitis BRisk of occupational infectionOccupational infectionInfection control practicesForensic autopsy populationImmunodeficiency virusHepatitis BInfectious disease testingTuberculosis infectionInfectious disease test resultsDiagnostic accuracyPostexposure managementInfectionSARS-CoV-2Autopsy populationAutopsyMicrobiological testsEbola virusPostmortem examinationDisease testingInfectious diseasesLaboratory personnelPreventive measuresDeath
2024
A predictive language model for SARS-CoV-2 evolution
Ma E, Guo X, Hu M, Wang P, Wang X, Wei C, Cheng G. A predictive language model for SARS-CoV-2 evolution. Signal Transduction And Targeted Therapy 2024, 9: 353. PMID: 39710752, PMCID: PMC11663983, DOI: 10.1038/s41392-024-02066-x.Peer-Reviewed Original ResearchConceptsSARS-CoV-2 evolutionHot mutation spotsFrequency of mutationsSequence dataS1 sequencesVital mutationsPredicted mutationsSARS-CoV-2 variantsMutationsViral evolutionSARS-CoV-2Viral pathogensMutation profilesVariantsImmune evasionSequenceMutation spotsPredictive language modelViral mutationsLanguage modelStrainViral infectionSemantic representationCxcl10 is protective during mouse-adapted SARS-CoV-2 infection
Majumdar S, Weaver J, Pontejo S, Minai M, Lu X, Gao J, Holmes G, Johnson R, Zhang H, Kelsall B, Farber J, Alves D, Murphy P. Cxcl10 is protective during mouse-adapted SARS-CoV-2 infection. Journal Of Leukocyte Biology 2024, 117: qiae252. PMID: 39607906, DOI: 10.1093/jleuko/qiae252.Peer-Reviewed Original ResearchSARS-CoV-2 infectionSARS-CoV-2Mouse-adapted strain of SARS-CoV-2Absence of CXCL10Associated with poor outcomesCXCL10-/- miceLungs of male miceInflammatory gene inductionAcute SARS-CoV-2 infectionMouse-adapted strainSevere COVID-19Wild type controlsCXCL10-deficientChemokine CXCL10Lymphocytic infiltrationSevere acute respiratory syndrome coronavirus 2Poor outcomeAcute respiratory syndrome coronavirus 2Circulating levelsMale miceRespiratory syndrome coronavirus 2Infected miceSARS-CoV-2 pathogenesisVirus loadCXCL10Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines
Kovalchik K, Hamelin D, Kubiniok P, Bourdin B, Mostefai F, Poujol R, Paré B, Simpson S, Sidney J, Bonneil É, Courcelles M, Saini S, Shahbazy M, Kapoor S, Rajesh V, Weitzen M, Grenier J, Gharsallaoui B, Maréchal L, Wu Z, Savoie C, Sette A, Thibault P, Sirois I, Smith M, Decaluwe H, Hussin J, Lavallée-Adam M, Caron E. Machine learning-enhanced immunopeptidomics applied to T-cell epitope discovery for COVID-19 vaccines. Nature Communications 2024, 15: 10316. PMID: 39609459, PMCID: PMC11604954, DOI: 10.1038/s41467-024-54734-9.Peer-Reviewed Original ResearchConceptsT cell epitopesT cellsCD8+ T cell epitopesT cell immunityT cell epitope discoverySARS-CoV-2T-cell-directed vaccinationDesigning effective vaccinesB7 supertypePatient's proteomesSARS-CoV-2 variantsVaccine epitopesViral antigensSpike antigenVaccine developmentEffective vaccineEpitope discoveryCOVID-19 vaccineVaccineEpitopesAntigenic featuresOmicron variantAntigenCOVID-19CD8SARS-CoV-2 reprograms murine alveolar macrophages to dampen flu
Tabachnikova A, Iwasaki A. SARS-CoV-2 reprograms murine alveolar macrophages to dampen flu. Trends In Immunology 2024, 45: 925-927. PMID: 39580310, DOI: 10.1016/j.it.2024.11.002.Peer-Reviewed Original ResearchCoverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024
Reses H, Segovia G, Dubendris H, Barbre K, Ananth S, Lape-Newman B, Wong E, Stillions M, Rowe T, Mothershed E, Wallender E, Twentyman E, Wiegand R, Patel P, Benin A, Bell J. Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents — National Healthcare Safety Network, United States, November 2024. MMWR Morbidity And Mortality Weekly Report 2024, 73: 1052-1057. PMID: 39570790, PMCID: PMC11581205, DOI: 10.15585/mmwr.mm7346a2.Peer-Reviewed Original ResearchConceptsRespiratory syncytial virusRespiratory syncytial virus vaccineNational Healthcare Safety NetworkSyncytial virusVaccination coverageSusceptible to severe outcomesHealth and Human Services regionsRespiratory virus seasonCOVID-19 vaccineCDC's National Healthcare Safety NetworkInfluenza vaccineVirus seasonSevere complicationsRespiratory virusesAssociated with respiratory illnessInfluenzaNursing home residentsSafety NetworkRespiratory illnessSevere outcomesReport vaccinationElevated riskSARS-CoV-2VaccineIndex levelsViral N protein hijacks deaminase-containing RNA granules to enhance SARS-CoV-2 mutagenesis
Li Z, Luo L, Ju X, Huang S, Lei L, Yu Y, Liu J, Zhang P, Chi T, Ma P, Huang C, Huang X, Ding Q, Zhang Y. Viral N protein hijacks deaminase-containing RNA granules to enhance SARS-CoV-2 mutagenesis. The EMBO Journal 2024, 43: 6444-6468. PMID: 39567830, PMCID: PMC11649915, DOI: 10.1038/s44318-024-00314-y.Peer-Reviewed Original ResearchRNA granulesHost deaminasesN proteinMutant N proteinPackage viral genomic RNASARS-CoV-2 nucleocapsid (N) proteinSARS-CoV-2 evolutionNucleocapsid (N) proteinViral genomic RNAVirus-host cell interactionsSARS-CoV-2 mutationsADAR deaminasesAntiviral restriction factorsRNA editingGenomic RNAImpaired viral replicationStress granulesRNA mutagenesisSARS-CoV-2Viral genomeMutagenesisBlock viral infectionViral RNARNACo-localizationA substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity
Li Y, Zhang X, Tai W, Zhuang X, Shi H, Liao S, Yu X, Mei R, Chen X, Huang Y, Liu Y, Liu J, Liu Y, Zhu Y, Wang P, Tian M, Yu G, Li L, Cheng G. A substitution at the cytoplasmic tail of the spike protein enhances SARS-CoV-2 infectivity and immunogenicity. EBioMedicine 2024, 110: 105437. PMID: 39531918, PMCID: PMC11603013, DOI: 10.1016/j.ebiom.2024.105437.Peer-Reviewed Original ResearchS proteinCytoplasmic tailFERM-binding motifTrans-complementation systemSpike proteinAmino acid substitutionsProline-to-leucine substitutionSystematic bioinformatics analysisHigh-frequency mutationsSARS-CoV-2 virionsBinding motifAcid substitutionsSARS-CoV-2Natural selectionBioinformatics analysisEzrin/radixin/moesin proteinsMolecular mechanismsMutationsOmicron variantProteinVaccine developmentMRNA vaccinesGlobal disseminationSARS-CoV-2 Omicron sublineagesSublineagesNo evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota
Parry R, Lytras S, Petrone M, Wille M, Crits-Christoph A, Gifford R, Saito A, Smura T, Peacock T. No evidence that mutations in SARS-CoV-2 variants of concern derive from homologous fragments in gut microbiota. Journal Of Virology 2024, 98: e01468-24. PMID: 39494907, PMCID: PMC11650967, DOI: 10.1128/jvi.01468-24.Peer-Reviewed Original ResearchBacterial sequencesViral RNA-dependent RNA polymeraseRNA-dependent RNA polymeraseSARS-CoV-2 variantsBacterial protein sequencesSARS-CoV-2 proteinsEvolution of mutationsRNA polymeraseIntrahost diversityProtein sequencesHomologous fragmentsNucleotide sequenceProtein databaseTemplate-switchingGut microbiotaSARS-CoV-2 VOCsViral genomeSARS-CoV-2Mutated fragmentsAmino acidsRdRpMutationsSequenceViral replicationProteinA phylogenetics and variant calling pipeline to support SARS-CoV-2 genomic epidemiology in the UK
Colquhoun R, O’Toole Á, Hill V, McCrone J, Yu X, Nicholls S, Poplawski R, Whalley T, Groves N, Ellaby N, Loman N, Connor T, Rambaut A. A phylogenetics and variant calling pipeline to support SARS-CoV-2 genomic epidemiology in the UK. Virus Evolution 2024, 10: veae083. PMID: 39493537, PMCID: PMC11529618, DOI: 10.1093/ve/veae083.Peer-Reviewed Original ResearchSARS-CoV-2 genome sequencesSARS-CoV-2 genomeGlobal phylogenetic contextCOVID-19 Genomics UKCOG-UKVariant callingGenome sequencePhylogenetic contextGenomic epidemiologyGenomic surveillanceSARS-CoV-2Public health decision makingHealth decision makingGenomeSequenceSARS-CoV-2 pandemicPhylogeneticallyUnited KingdomQuality controlDecision makingCOVID-19Increasing amountDiacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study
Carmo H, Castillo A, Bonilha I, Gomes E, Barreto J, Moura F, Davanzo G, de Brito Monteiro L, Muraro S, de Souza G, Morari J, Galdino F, Brunetti N, Reis-de-Oliveira G, Carregari V, Nadruz W, Martins-de-Souza D, Farias A, Velloso L, Proenca-Modena J, Mori M, Loh W, Bhatt D, Yellon D, Davidson S, De Oliveira P, Moraes-Vieira P, Sposito A. Diacerein reduces inflammasome activation and SARS-CoV-2 virus replication: a proof-of-concept translational study. Frontiers In Pharmacology 2024, 15: 1402032. PMID: 39434905, PMCID: PMC11491754, DOI: 10.3389/fphar.2024.1402032.Peer-Reviewed Original ResearchPeripheral blood mononuclear cellsHuman peripheral blood mononuclear cellsSARS-CoV-2 infectionSARS-CoV-2Viral replicationInflammatory responseInflammasome activationMarkers of inflammasome activationPlacebo-controlled studySuppress viral replicationBlood mononuclear cellsInfection in vitroPrimary metabolitesCOVID-19 patientsDouble-blindPrimary endpointHealthy volunteersSevere acute respiratory syndrome coronavirus 2Plasma markersAcute respiratory syndrome coronavirus 2Mononuclear cellsClinical trialsRespiratory syndrome coronavirus 2Day 2Syndrome coronavirus 2A Cross-Sectional Study Revealed a Low Prevalence of SARS-CoV-2 Infection among Asymptomatic University Students in Tripoli, North Lebanon
Rafei R, Tajer L, Nour D, Abboud K, Ankoud D, Osman M, Bedotto M, Ismail M, Dabboussi F, Colson P, Hamze M. A Cross-Sectional Study Revealed a Low Prevalence of SARS-CoV-2 Infection among Asymptomatic University Students in Tripoli, North Lebanon. Pathogens 2024, 13: 872. PMID: 39452743, PMCID: PMC11510414, DOI: 10.3390/pathogens13100872.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply